A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B

Summary

This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.

Timeline

Start

2018-01-22

Primary completion

2022-08-31

Completion

2022-09-23

Outcome

Met primary endpoint

registry analysis (superiority test); NT-501 vs Sham; p = 0.0186; Median Difference (Final Values) -0.049 (95% CI -0.0890 to -0.0082); Mixed Models Analysis NCT03319849 ↗

Publications

• Chew EY, Gillies M, Jaffe GJ, Gaudric A, Egan C, Constable I, Clemons T, Aaberg T, Manning DC, Hohman TC, Bird A, Friedlander M; MacTel CNTF NTMT-03 Research investigators. Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2. NEJM Evid. 2025 Aug;4(8):EVIDoa2400481. doi: 10.1056/EVIDoa2400481. Epub 2025 Jul 22.

Drugs

Indications